Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? - PubMed (original) (raw)
. 2009 Jul 20;27(21):3459-64.
doi: 10.1200/JCO.2008.20.4669. Epub 2009 May 11.
Sven Perner, Meir J Stampfer, Jennifer A Sinnott, Stephen Finn, Anna S Eisenstein, Jing Ma, Michelangelo Fiorentino, Tobias Kurth, Massimo Loda, Edward L Giovannucci, Mark A Rubin, Lorelei A Mucci
Affiliations
- PMID: 19433685
- PMCID: PMC2717753
- DOI: 10.1200/JCO.2008.20.4669
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
Jennifer R Stark et al. J Clin Oncol. 2009.
Abstract
PURPOSE Gleason grading is an important predictor of prostate cancer (PCa) outcomes. Studies using surrogate PCa end points suggest outcomes for Gleason score (GS) 7 cancers vary according to the predominance of pattern 4. These studies have influenced clinical practice, but it is unclear if rates of PCa mortality differ for 3 + 4 and 4 + 3 tumors. Using PCa mortality as the primary end point, we compared outcomes in Gleason 3 + 4 and 4 + 3 cancers, and the predictive ability of GS from a standardized review versus original scoring. PATIENTS AND METHODS Three study pathologists conducted a blinded standardized review of 693 prostatectomy and 119 biopsy specimens to assign primary and secondary Gleason patterns. Tumor specimens were from PCa patients diagnosed between 1984 and 2004 from the Physicians' Health Study and Health Professionals Follow-Up Study. Lethal PCa (n = 53) was defined as development of bony metastases or PCa death. Hazard ratios (HR) were estimated according to original GS and standardized GS. We compared the discrimination of standardized and original grading with C-statistics from models of 10-year survival. Results For prostatectomy specimens, 4 + 3 cancers were associated with a three-fold increase in lethal PCa compared with 3 + 4 cancers (95% CI, 1.1 to 8.6). The discrimination of models of standardized scores from prostatectomy (C-statistic, 0.86) and biopsy (C-statistic, 0.85) were improved compared to models of original scores (prostatectomy C-statistic, 0.82; biopsy C-statistic, 0.72). CONCLUSION Ignoring the predominance of Gleason pattern 4 in GS 7 cancers may conceal important prognostic information. A standardized review of GS can improve prediction of PCa survival.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
Comparison of standardized and original Gleason scores assigned to prostatectomy specimens during three time periods. The Gleason scores and the best fitting line through the points are plotted in gold. The blue line represents perfect concordance between original and standardized scores.
Fig 2.
Discrimination of models including Gleason data from original source versus standardized review of prostatectomy specimens. C-statistics from models of 10-year survival with Gleason score categorized as a 10-level ordinal variable for Gleason scores 2 to 10 (with separate codes for Gleason 3 + 4 and 4 + 3). Standardized Gleason score C-statistic, 0.86; original Gleason score C-statistic, 0.82.
Similar articles
- Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M, Berg KD, Brasso K, Iversen P, Røder MA. Heering M, et al. Surg Oncol. 2017 Mar;26(1):21-27. doi: 10.1016/j.suronc.2016.12.002. Epub 2016 Dec 8. Surg Oncol. 2017. PMID: 28317581 - New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M. Ham WS, et al. Eur Urol. 2017 Jun;71(6):907-912. doi: 10.1016/j.eururo.2016.11.006. Epub 2016 Nov 19. Eur Urol. 2017. PMID: 27876305 - The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.
Helpap B, Ringli D, Tonhauser J, Poser I, Breul J, Gevensleben H, Seifert HH. Helpap B, et al. Pathol Oncol Res. 2016 Apr;22(2):349-56. doi: 10.1007/s12253-015-0013-x. Epub 2015 Nov 12. Pathol Oncol Res. 2016. PMID: 26563277 - Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
Kır G, Seneldir H, Gumus E. Kır G, et al. Ann Diagn Pathol. 2016 Feb;20:48-51. doi: 10.1016/j.anndiagpath.2015.10.013. Epub 2015 Dec 2. Ann Diagn Pathol. 2016. PMID: 26750655 - Multiparametric MRI in detection and staging of prostate cancer.
Boesen L. Boesen L. Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review.
Cited by
- RAD21 promotes oncogenesis and lethal progression of prostate cancer.
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, Lu K, Janas T, Hu S, Vander Heiden MG, Loda M, Boselli M, Amon A, Mucci LA. Su XA, et al. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2405543121. doi: 10.1073/pnas.2405543121. Epub 2024 Aug 27. Proc Natl Acad Sci U S A. 2024. PMID: 39190349 Free PMC article. - Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction.
Sun R, A J, Yu H, Wang Y, He M, Tan L, Cheng H, Zhang J, Wang Y, Sun X, Lyu M, Qu M, Huang L, Li Z, Zhang W, Ma K, Dong Z, Ge W, Zhang Y, Ding X, Yang B, Hou J, Xu C, Wang L, Zhu Y, Guo T, Gao X, Yang C. Sun R, et al. Cell Rep Med. 2024 Aug 20;5(8):101679. doi: 10.1016/j.xcrm.2024.101679. Cell Rep Med. 2024. PMID: 39168102 Free PMC article. - Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients.
Talia M, Cesario E, Cirillo F, Scordamaglia D, Di Dio M, Zicarelli A, Mondino AA, Occhiuzzi MA, De Francesco EM, Belfiore A, Miglietta AM, Di Dio M, Capalbo C, Maggiolini M, Lappano R. Talia M, et al. J Transl Med. 2024 Jun 27;22(1):597. doi: 10.1186/s12967-024-05413-2. J Transl Med. 2024. PMID: 38937754 Free PMC article. - The Current Therapeutic Landscape for Metastatic Prostate Cancer.
Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G. Bernal A, et al. Pharmaceuticals (Basel). 2024 Mar 8;17(3):351. doi: 10.3390/ph17030351. Pharmaceuticals (Basel). 2024. PMID: 38543137 Free PMC article. Review. - Advanced strain elastography is a reliable approach for prostate cancer detection in patients with elevated PSA levels.
Almalki YE, Mansour MGE, Ali SA, Basha MAA, Abdelkawi MM, Alduraibi SK, Almushayti ZA, Aldhilan AS, Aboualkheir M, Amin D, Metkees M, Basha AMA, Ebaid NY. Almalki YE, et al. Sci Rep. 2024 Feb 5;14(1):2917. doi: 10.1038/s41598-024-53440-2. Sci Rep. 2024. PMID: 38316992 Free PMC article.
References
- Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol. 1992;23:273–279. - PubMed
- Andren O, Fall K, Franzen L, et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006;175:1337–1340. - PubMed
- Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58–64. - PubMed
- D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974. - PubMed
- Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248–1253. - PubMed
Publication types
MeSH terms
Grants and funding
- HL-34595/HL/NHLBI NIH HHS/United States
- HL-26490/HL/NHLBI NIH HHS/United States
- R01 HL034595/HL/NHLBI NIH HHS/United States
- CA097193/CA/NCI NIH HHS/United States
- T32CA009001-32/CA/NCI NIH HHS/United States
- R01 CA058684/CA/NCI NIH HHS/United States
- 5R01CA042182-20/CA/NCI NIH HHS/United States
- T32 CA009001/CA/NCI NIH HHS/United States
- 5R01CA058684-13/CA/NCI NIH HHS/United States
- R01 CA040360/CA/NCI NIH HHS/United States
- R01 CA034944/CA/NCI NIH HHS/United States
- R01 CA042182/CA/NCI NIH HHS/United States
- R01 HL026490/HL/NHLBI NIH HHS/United States
- R01 CA097193/CA/NCI NIH HHS/United States
- CA40360/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical